Avantor (NYSE: AVTR) taps Ludovic Brellier to lead BMP and transformation
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Avantor, Inc. announced a leadership transition in its Bioscience & Medtech Products segment. The company hired Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products and Chief Transformation Officer, effective May 1, 2026, to lead growth, operational performance and the Revival Management Office.
The current Executive Vice President, Bioscience and Medtech Products, Benoit Gourdier, will move into a role supporting segment integration activities and is expected to depart the company no later than December 31, 2026. The changes focus on business transformation and integration across Avantor’s enterprise.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Start date for Ludovic Brellier: May 1, 2026
Expected departure date for Benoit Gourdier: December 31, 2026
Press release date: April 23, 2026
+1 more
4 metrics
Start date for Ludovic Brellier
May 1, 2026
Effective date as EVP, Bioscience & Medtech Products and Chief Transformation Officer
Expected departure date for Benoit Gourdier
December 31, 2026
Latest expected date for his departure from Avantor
Press release date
April 23, 2026
Date Avantor announced hiring of Ludovic Brellier
8-K event date
April 17, 2026
Date Avantor informed Benoit Gourdier of transition and expected departure
Key Terms
Chief Transformation Officer, Revival Management Office, Regulation FD Disclosure, Emerging growth company
4 terms
Chief Transformation Officer financial
"will join the company as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer"
A chief transformation officer is the senior executive responsible for planning and overseeing major changes to how a company operates, such as reorganizing teams, updating technology, or shifting business strategy. Investors care because successful transformation can boost efficiency, cut costs, open new revenue streams or reduce risk—much like a renovation manager who retools a house to increase its value and appeal to buyers.
Revival Management Office financial
"He will also lead the Revival Management Office, driving transformation initiatives across the enterprise."
Regulation FD Disclosure regulatory
"Item 7.01. Regulation FD Disclosure. On April 23, 2026, the Company issued a press release"
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
Emerging growth company regulatory
"Emerging growth company Item 5.02. Departure of Directors or Certain Officers"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 17, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 17, 2026, Avantor, Inc. (the “Company”) informed Benoit Gourdier, the Company’s Executive Vice President, Bioscience and Medtech Products, that he would be transitioning to a new role supporting the Company’s segment integration activities, after which it is expected that he would depart the Company no later than December 31, 2026.
Item 7.01. Regulation FD Disclosure.
On April 23, 2026, the Company issued a press release announcing the hiring of Ludovic Brellier to serve as the Company’s Executive Vice President, Bioscience and Medtech Products and Chief Transformation Officer effective May 1, 2026. A copy of the press release is furnished herewith as Exhibit No. 99 to this Current Report on Form 8-K, and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed to be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |||||||
99 | Press Release, dated April 23, 2026 | |||||||
| 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Avantor, Inc. | |||||||||||
| Date: April 23, 2026 | By: | /s/ Claudius Sokenu | |||||||||
| Name: | Claudius Sokenu | ||||||||||
| Title: | Executive Vice President, Chief Legal and Compliance Officer and Secretary | ||||||||||
News release FOR IMMEDIATE RELEASE Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer RADNOR, Pa. – April 23, 2026 – Avantor, Inc. (NYSE: AVTR), a leading global provider of mission- critical products and services to customers in the life sciences and advanced technology industries, today announced that Ludovic Brellier will join the company as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer on May 1, 2026. In this role, Mr. Brellier will be responsible for growing the BMP business and improving operational performance. He will also lead the Revival Management Office, driving transformation initiatives across the enterprise. Mr. Brellier is an accomplished executive with deep operational experience across healthcare and strategic business transformation. He joins Avantor from Danaher, where he was most recently President of Cytiva’s Hardware Solutions business, leading five business units responsible for early innovation through manufacturing and commercialization of services for the biopharma industry. While at Cytiva, Mr. Brellier previously served as President of Integrated Solutions & Services and VP Business Operations. He also led the effort to establish Cytiva as a standalone operating company within Danaher as well as the integration of Pall Life Sciences and Cytiva. “Ludovic is a skilled operator who has a successful track record of growing bioprocessing businesses both organically and inorganically, and our BMP segment is a strong platform that has a lot of potential for growth under his leadership,” said Emmanuel Ligner, Avantor’s President and CEO. “As we execute Revival across our enterprise, Ludovic’s past transformation and integration experience will be critical.” Ligner concluded. Mr. Brellier added, “Avantor’s bioprocessing platform has leading product brands with rich legacies and strong customer preference. I look forward to leveraging my manufacturing and commercialization skills to enhance our operations and drive sustainable growth in the business by enabling the product brands to reach their full potential. The successful execution of Revival will be critical to the success of both Avantor’s business segments,” Brellier concluded. Benoit Gourdier, current Executive Vice President of Avantor’s BMP Segment, will stay with the company until on or before the end of 2026 to ensure a smooth transition. About Avantor Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine,
page | 2 healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook. Investor Relations Contact Chris Fidyk Vice President, Investor Relations Avantor Chris.Fidyk@avantorsciences.com Global Media Contact Eric Van Zanten Head of External Communications Avantor 610-529-6219 Eric.VanZanten@avantorsciences.com SOURCE: Avantor and Financial News
FAQ
What executive leadership change did Avantor (AVTR) announce in this 8-K?
Avantor announced that Ludovic Brellier will become Executive Vice President, Bioscience & Medtech Products and Chief Transformation Officer on May 1, 2026. He will oversee growth, operations, and transformation initiatives, while current EVP Benoit Gourdier transitions to an integration role before leaving by year-end 2026.
Who is Ludovic Brellier in the Avantor (AVTR) leadership update?
Ludovic Brellier is an executive with extensive healthcare and transformation experience who will join Avantor on May 1, 2026. He previously held senior roles at Danaher’s Cytiva business, leading multiple units focused on innovation, manufacturing, services and large integrations in the biopharma industry.
What responsibilities will Avantor’s new Chief Transformation Officer have?
As Chief Transformation Officer, Ludovic Brellier will be responsible for improving operational performance and driving transformation initiatives across Avantor. He will lead the Revival Management Office, focusing on enterprise-wide change while also growing the Bioscience & Medtech Products business segment in line with the company’s strategy.
What is the planned timing of Benoit Gourdier’s departure from Avantor (AVTR)?
Avantor expects Benoit Gourdier, current Executive Vice President of the BMP segment, to leave the company on or before December 31, 2026. Until then, he will transition into a role focused on supporting segment integration activities and ensuring a smooth handover to his successor.
What is the Revival Management Office mentioned in Avantor’s announcement?
The Revival Management Office is an internal Avantor function that coordinates transformation initiatives across the enterprise. Under Ludovic Brellier’s leadership as Chief Transformation Officer, it will support the company’s Revival program aimed at improving performance and executing strategic change in both business segments.
How did Avantor (AVTR) communicate the hiring of Ludovic Brellier?
Avantor issued a press release on April 23, 2026, announcing the hiring of Ludovic Brellier, which was furnished as Exhibit 99 to the Form 8-K. The company noted the release is furnished, not filed, under the Exchange Act and is not automatically incorporated into other securities filings.